Protective Effects of Isostrictiniin Against High-Fat, High-Sugar Diet-Induced Steatosis in MASLD Mice via Regulation of the AMPK/SREBP-1c/ACC Pathway

Nutrients. 2024 Nov 13;16(22):3876. doi: 10.3390/nu16223876.

Abstract

Objectives: Isostrictiniin (ITN), a natural polyphenol extracted from Nymphaea candida (snow-white waterlily), has antioxidant and hepatoprotective activities that may be beneficial in treating metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to investigate the protective effects of ITN on high-fat, high-sugar diet (HFSD)-induced steatosis in MASLD mice and its mechanisms.

Methods: Kunming mice were randomly divided into normal control and HFSD groups. After being fed for 4 weeks, the HFSD group was randomly divided into model, atorvastatin calcium (ATC; 10 mg/kg), and ITN (25, 50, and 100 mg/kg) groups. After continued feeding for 4 weeks, the biochemical indexes in the mice were determined.

Results: Compared with the model group, the liver index; FBG; HOMA-IR; serum AST, ALT, TG, TC, and LDL-C; and liver MDA, IL-6, TNF-α, and IL-1β levels in the ITN (25, 50, and 100 mg/kg) and ATC (10 mg/kg) groups were significantly decreased (p < 0.05), while serum HDL-C and liver SOD and GSH-Px levels were increased (p < 0.05). Pathological observation showed that ITN treatment mitigated the lipid liver deposition in the HFSD mice. Moreover, ITN could upregulate liver-tissue p-AMPK/AMPK protein expression in the HFSD-induced MASLD mice and downregulate SREBP-1c and ACC levels (p < 0.05).

Conclusions: ITN can significantly improve MASLD mice, and its mechanism may be related to the regulation of the AMPK/SREBP-1c/ACC pathway.

Keywords: AMPK/SREBP-1c/ACC pathway; MSALD; high-fat–high-sugar diets; isostrictiniin.

MeSH terms

  • AMP-Activated Protein Kinases* / metabolism
  • Acetyl-CoA Carboxylase* / metabolism
  • Animals
  • Animals, Outbred Strains
  • Diet, High-Fat* / adverse effects
  • Dietary Sugars / adverse effects
  • Disease Models, Animal
  • Fatty Liver / drug therapy
  • Fatty Liver / etiology
  • Fatty Liver / prevention & control
  • Liver* / drug effects
  • Liver* / metabolism
  • Liver* / pathology
  • Male
  • Mice
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / etiology
  • Signal Transduction / drug effects
  • Sterol Regulatory Element Binding Protein 1* / metabolism

Substances

  • Sterol Regulatory Element Binding Protein 1
  • AMP-Activated Protein Kinases
  • Acetyl-CoA Carboxylase
  • Srebf1 protein, mouse
  • Dietary Sugars

Supplementary concepts

  • Kunming mice